Matching articles for "Radicava"
Issue 1681 · July 24, 2023
Tofersen (Qalsody) for ALS

Tofersen ( Qalsody – Biogen), an intrathecally administered antisense oligonucleotide, has received accelerated approval from the FDA for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a…

Med Lett Drugs Ther. 2023 Jul 24; 65(1681):113-4 doi:10.58347/tml.2023.1681a
Tofersen ( Qalsody – Biogen), an intrathecally administered antisense oligonucleotide, has received accelerated approval from the FDA for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. About 2% of patients with ALS have mutations in the SOD1 gene. Tofersen is the first drug to be approved in the US that targets a genetic cause of ALS. Accelerated approval of the drug was based on the surrogate endpoint of a reduction in plasma neurofilament light chain, which is considered likely to predict clinical benefit.
Issue 1664 · November 28, 2022
Relyvrio for ALS

The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate ( Buphenyl , and others)…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):190-1
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate ( Buphenyl , and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole ( Rilutek , and others) and edaravone (Radicava, Radicava ORS) were approved earlier.
Issue 1658 · September 5, 2022 Free
In Brief: Edaravone Oral Suspension (Radicava ORS) for ALS (online only)

Radicava ORS , an oral suspension formulation of the free radical scavenger edaravone (Mitsubishi Tanabe Pharma), has been approved by the FDA for treatment of amyotrophic lateral sclerosis (ALS). An IV…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):e1
Radicava ORS , an oral suspension formulation of the free radical scavenger edaravone (Mitsubishi Tanabe Pharma), has been approved by the FDA for treatment of amyotrophic lateral sclerosis (ALS). An IV formulation of edaravone (Radicava) has been available since 2017.
Issue 1533 · November 6, 2017
Edaravone (Radicava) for ALS

The FDA has approved edaravone ( Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole (…

Med Lett Drugs Ther. 2017 Nov 6; 59(1533):180-2
The FDA has approved edaravone ( Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole ( Rilutek , and generics) was approved in 1995. Edaravone was approved for treatment of ALS as Radicut in Japan and South Korea in 2015. It has been used in Japan and other Asian countries since 2001 for treatment of acute ischemic stroke.